Alpha Tau Medical stock, REGAIN trial

Alpha Tau Medical stock: REGAIN trial reports objective responses

Published on 11/18/2026 at 02:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Alpha Tau Medical stock follows interim REGAIN data from a small glioblastoma trial. Six evaluable patients showed objective responses as follow-up continues.

REGAIN trial delivers interim signals

  • All eight treated patients were alive as of November 11, while median overall survival had not been reached.
  • Five of six evaluable patients achieved a complete response under RANO criteria, and one recorded a partial response.
  • Alpha Tau plans to continue enrollment and follow-up toward a 20-patient study.
Alpha Tau Medical stock, REGAIN trial, glioblastoma, Alpha DaRT, clinical research, Illustration mit AI erstellt.

Alpha Tau Medical announced updated interim results from its U.S. REGAIN trial on November 15, 2026, reporting objective responses in all six patients who had reached assessment. The company said the findings were presented at the Society for Neuro-Oncology annual meeting in Philadelphia. The company announcement described the results as interim and said additional follow-up is expected to clarify several imaging findings.

Responses reported in REGAIN study

Eight patients had been treated by the November 11 cutoff, and all remained alive. Among the six patients who reached MRI response assessment, five achieved a complete response and one achieved a partial response, with a 58 percent decrease in tumor measurements. Median overall survival had not been reached after a median follow-up of 6.9 months among the six assessed patients.

Alpha Tau said planned Alpha DaRT sources were deployed in all eight treated patients, meeting the study's feasibility objective. No unanticipated serious adverse events had been observed, while a previously reported grade 3 seizure involving Todd's paralysis had resolved with steroids. The company also said no definitive recurrence had been observed within the treated area by the cutoff date.

Follow-up remains central for investors

The findings come from a small, ongoing study designed primarily to assess feasibility and safety. The responses in the three most recently assessed patients remain subject to confirmation on subsequent scans, and two patients have imaging findings that investigators are evaluating for possible necrosis or tumor progression.

REGAIN is designed to enroll up to 20 U.S. patients with recurrent glioblastoma who are not candidates for surgical resection and have previously received central nervous system radiation. Further imaging, patient follow-up and enrollment will determine how durable the early signals prove to be.

Alpha Tau's oncology platform

Alpha Tau Medical is an Israeli clinical-stage oncology company developing intratumoral alpha-emitting radiotherapeutics for solid tumors. Its Alpha DaRT technology uses radium-224 sources placed inside tumors and is being evaluated in brain, pancreatic, skin and head and neck, prostate and lung cancers. The company is also studying the treatment as a stand-alone therapy and in combination with systemic agents, according to its company overview.

Alpha Tau Medical at a glance

  • Company: Alpha Tau Medical Ltd.
  • Nasdaq ticker: DRTS
  • Home market: Israel
  • Lead platform: Alpha DaRT intratumoral alpha-emitting radiotherapeutic
  • Study: REGAIN recurrent glioblastoma trial

Israeli equities trade against the broader backdrop of the TA-35.

Disclaimer...
en | boerse | 70529147 |